US 12,070,478 B2
Cancer immunotherapy using virus particles
Nicole F. Steinmetz, San Diego, CA (US); and Karin L. Lee, Cleveland, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed on Feb. 28, 2023, as Appl. No. 18/115,066.
Application 18/115,066 is a continuation of application No. 16/492,884, granted, now 11,590,183, previously published as PCT/US2018/022023, filed on Mar. 12, 2018.
Application 16/492,884 is a continuation in part of application No. 15/589,677, filed on May 8, 2017, granted, now 10,639,363, issued on May 5, 2020.
Claims priority of provisional application 62/469,869, filed on Mar. 10, 2017.
Prior Publication US 2024/0058401 A1, Feb. 22, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/76 (2015.01); A61K 31/704 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61P 35/00 (2006.01); C12N 7/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 35/76 (2013.01) [A61K 31/704 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61P 35/00 (2018.01); A61K 45/06 (2013.01); C12N 2770/26011 (2013.01); C12N 2770/26023 (2013.01); C12N 2770/26033 (2013.01); C12N 2770/26042 (2013.01); C12N 2770/40023 (2013.01)] 20 Claims
 
1. A method of treating cancer in a subject in need thereof, comprising administering directly to the cancer a therapeutically effective amount of an in situ vaccine, the in situ vaccine including at least one of potato virus X (PVX) or PVX virus-like particles, and an anti-cancer agent, wherein the PVX or PVX virus-like particles are not used as a vehicle for drug or antigen delivery.